Journal article
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
GR Foster, K Chayama, WL Chuang, H Fainboim, M Farkkila, A Gadano, GB Gaeta, C Hézode, Y Inada, J Heo, H Kumada, SN Lu, P Marcellin, C Moreno, SK Roberts, SI Strasser, AJ Thompson, J Toyota, SW Paik, JM Vierling Show all
Springerplus | SPRINGER INTERNATIONAL PUBLISHING AG | Published : 2016
Open access
Abstract
Background and purpose: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection. Methods: In this multicenter, double-blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome measure was sustained virologic response at post-treatment Week 12 (SVR1..
View full abstractGrants
Funding Acknowledgements
This study was funded by Bristol-Myers Squibb.